Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Terminated NCT05539157

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Conditions: Cutaneous Tumor, Malignant Solid Tumor

Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 1
Sponsor: Immorna Biotherapeutics, Inc.

Location: University of Texas M. D. Anderson Cancer Center Houston Texas

Summary

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors

Eligibility Criteria

Inclusion Criteria: All of the following conditions should be met at screening: * Male or female patients 18-75 * Patients with malignant solid tumors that have been diagnosed by pathology and/or cytology * Patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist * Patients with at least one non-injected measurable tumor lesion per RECIST v1.1 * Patients with lesions suitable for intratumoral injection (the lesion length is at least 10 mm and not exceeding 80 mm) * Patients enrolled in the single and multiple administration stages of Phase 1a must agree to provide pre- and post-treatment tumor biopsy tissues * Patients must have adequate organ and marrow functions * Patients with treated brain metastases are eligible if meeting protocol's requirement * Patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other investigational therapy or radiotherapy Exclusion Criteria: Patients who meet any of the following criteria will be excluded from study entry: * Patients who have received prior IL-12 either alone or as part of a treatment regimen * Patients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) * Patients requiring therapeutic doses of anticoagulation * Patients with tumors that impinge on major airways, blood vessels, or nerve bundles * Patients with a history of autoimmune disease that has the possibility of recurrence or active autoimmune disease that requires immunosuppressive medications * Patients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment * Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment * Patient with history of solid organ or allogenic bone marrow transplantation

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05539157). StuddyBuddy aggregates publicly available trial information.